This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechnology: Archive
REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase
by Zacks Equity Research
Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand.
biotechnology earnings medical pharmaceuticals
INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales
by Zacks Equity Research
Incyte posts strong Q3 results as higher sales of Jakafi, Opzelura and new launches drive revenue and earnings beats.
biotechnology biotechs earnings medical pharmaceuticals
Should Investors Buy CorMedix Stock Ahead of Q3 Earnings Report?
by Ahan Chakraborty
CRMD's Q3 momentum, fueled by DefenCath's strong uptake and Melinta's revenue boost, positions the stock for continued growth.
biotechnology biotechs hospitals medical pharmaceuticals
EastGroup Properties (EGP)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues
by Zacks Equity Research
RDY posts a Q2 earnings and revenue beat as global generics drive growth, while new launches and biosimilar advances shape its pipeline.
biotechnology biotechs earnings medical pharmaceuticals
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
by Ahan Chakraborty
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings?
by Zacks Equity Research
Bristol-Myers Squibb's Q3 results hinge on rising demand for new therapies like Opdivo and Camzyos amid legacy-drug declines.
biotechnology biotechs earnings medical pharmaceuticals
PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now?
by Ekta Bagri
Bristol Myers edges past Pfizer as the stronger oncology pick, backed by new drug launches, acquisitions and pipeline strength
biotechnology biotechs medical pharmaceuticals
Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
INCY eyes strong Q3 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
biotechnology biotechs earnings medical pharmaceuticals
REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?
by Zacks Equity Research
Regeneron's Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition.
biotechnology biotechs medical pharmaceuticals